Internal Medicine, Pulmonary Disease · Dallas, TX
NPI
1801179759
Since 2011
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
5
Medicare group memberships
Hospitals
2
Hospital affiliations
7777 Forest Ln Ste C520
Dallas, TX, 75230
Phone (936) 499-0341
Groups this clinician bills Medicare through
Medicare paid, 2024
$144K
2,097 services
Medicare patients, 2024
642
Average age 75
Drug cost, 2024
$1.4M
2,899 prescriptions
Company payments, 2025
$1,463
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amaya D Skabelund was code 99214 (office e&m - established), 577 times for 311 patients. In total Amaya D Skabelund billed 2,097 services in 55 codes, and Medicare paid $144K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-11-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 577 | 311 | $74.32 | $43K |
| 99233 Hospital E&M - Subsequent | Facility | 476 | 202 | $92.58 | $44K |
| 99204 Office E&M - New | Facility | 101 | 101 | $100.10 | $10K |
| 94726 Pulmonary Function Testing | Facility | 90 | 86 | $8.90 | $801 |
| 94729 Pulmonary Function Testing | Facility | 89 | 85 | $6.61 | $588 |
| 94060 Pulmonary Function Testing | Facility | 86 | 83 | $7.62 | $655 |
| 31628 Bronchoscopy | Facility | 70 | 66 | $71.88 | $5,031 |
| 31654 Bronchoscopy | Facility | 67 | 63 | $52.30 | $3,504 |
| 31627 Bronchoscopy | Facility | 65 | 61 | $75.23 | $4,890 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Facility | 59 | 51 | $12.77 | $754 |
| 99407 Behavioral Health Services | Facility | 54 | 43 | $24.57 | $1,327 |
| 94618 Pulmonary Function Testing | Facility | 36 | 32 | $16.83 | $606 |
| 31629 Bronchoscopy | Facility | 35 | 34 | $143.68 | $5,029 |
| 31624 Bronchoscopy | Facility | 29 | 27 | $23.86 | $692 |
| 32555 Other Organ Systems | Facility | 27 | 22 | $83.70 | $2,260 |
By year: 2022 $146K for 2,196 services; 2023 $139K for 2,114 services; 2024 $144K for 2,097 services.
Medicare prescription drug claims, 2024
In 2024, the drug Amaya D Skabelund prescribed most often to Medicare patients was Albuterol Sulfate Hfa (Albuterol Sulfate), with 350 prescriptions and refills. In total Amaya D Skabelund wrote 2,899 Medicare prescriptions that cost $1.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Albuterol Sulfate Hfa Albuterol Sulfate | 350 | 431 | 112 | $11K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 342 | 455 | 73 | $265K |
| Stiolto Respimat Tiotropium Br/Olodaterol Hcl | 327 | 373 | 71 | $175K |
| Omeprazole Generic | 165 | 292 | 54 | $2,420 |
| Mycophenolate Mofetil Generic | 144 | 173 | 27 | $15K |
| Prednisone Generic | 122 | 160 | 73 | $657 |
| Azithromycin Generic | 84 | 99 | 28 | $1,022 |
| Montelukast Sodium Generic | 68 | 152 | 26 | $826 |
| Ventolin Hfa Albuterol Sulfate | 62 | 66 | 26 | $3,977 |
| Bevespi Aerosphere Glycopyrrolate/Formoterol Fum | 57 | 69 | 14 | $27K |
| Advair Hfa Fluticasone Propion/Salmeterol | 56 | 68 | 13 | $26K |
| Furosemide Generic | 50 | 88 | 19 | $215 |
| Rifampin Generic | 46 | 54 | Under 11 | $1,720 |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 41 | 51 | Under 11 | $31K |
| Bumetanide Generic | 40 | 71 | 13 | $1,926 |
Brand drugs: 1,388 claims; generic drugs: 1,511 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amaya D Skabelund $1,463 ($1,463 in general payments such as food, travel and fees) from 3 companies. The largest payer was Intuitive Surgical, Inc. with $884.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.